Navigation Links
Bavarian Nordic Publishes its Annual Results 2008
Date:3/27/2009

ions in Actavis A/S.

Bavarian Nordic awards warrants

The Board of Directors in Bavarian Nordic A/S has today decided to award warrants to a member of executive management and employees in the Company and its subsidiaries. The Board decision is made in accordance with the shareholder authorisation for the Board of Directors adopted as Article 5f of the Articles of Association and the Company's guidelines regarding incentive programs. The award is made by the Board of Directors and exercise is limited by and governed by the Danish Act on Options for Employees (the Stock Option Act/aktieoptionsloven) regarding termination of employment prior to exercise of warrants.

A total of 25,000 warrants are awarded for subscription of up to 25,000 shares of a nominal value of DKK 10 at an exercise price of DKK 124 per share. The exercise price has been established on the basis of the average share price ("closing price") for the Company's share in a period of 15 business days prior to this day added a 15 % premium. However, the exercise price must at least be equal to the Company's average exchange-listed price today. In the event that the average exchange-listed price on the Company's shares today exceeds DKK 124 the exercise price shall be increased accordingly. If this becomes relevant the Company will make a separate announcement to NASDAQ OMX.

The warrants can be exercised wholly or partly in a period of 14 days commencing from the day of publication of the Company's Annual Report for 2011, from the day of publication of the Company's Half Yearly Interim Results for 2012, from the day of publication of the Company's Annual Report for 2012 and in a period of 14 days commencing from the day of publication of the Company's Half Yearly Interim Results for 2013.

Referring to the Danish Securities Act, Section 28a it is announced that Steen Vangsgaard, who is a member of executive manageme
'/>"/>

SOURCE Bavarian Nordic A/S
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Bavarian Nordic Receives $50 Million Advance Payment from HHS for Fulfilling Contract Milestones
2. Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strategy Process
3. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
4. Bavarian Nordic Receives USD 25 Million Milestone Payment After Submission of Important IMVAMUNE(R) Data to The U.S. Health Authorities
5. Bavarian Nordics Case Against Oxford BioMedica
6. Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting
7. Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R)
8. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
9. Consortium publishes Phase II map of human genetic variation
10. The Lancet Publishes Vasogens ACCLAIM Results
11. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...ire/ -- Calbiotech, Inc. announced today that it h...ch (SBIR) Phase I contract by the U.S. Army Medica...e agreement, Calbiotech will develop analyte speci...rus. ,, Dengue virus is a mosquito-born flav...forces deployed to tropical areas of the world. Du...
(Date:11/5/2009)...FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC ) today ...ter ended September 30, 2009. GenVec reported a ne...hree months ended September 30, 2009 compared to a... comparable quarter of 2008. For the nine months e....1 million ($0.15 per share), compared to a net lo...
(Date:11/5/2009)...5, 2009 at 4:30 p.m. Eastern Time , BOTHELL, ...ncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the...ted financial results for the third quarter and ni...e Company,s highlights for the third quarter of 20...ct the operations of OncoGenex Technologies Inc. (...
(Date:11/5/2009)...swire-FirstCall/ -- Senomyx, Inc. (Nasdaq: SNMX )...eptor-based technologies to discover novel flavor ... supply industries, today provided a corporate upd...uarter ended September 30, 2009. Revenues were $4... to $4.0 million for the third quarter of 2008, an...
Breaking Biology Technology:Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus 2GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14
...ution Enables Enhanced Productivity and Decreased ...e global leader,in helping academic, healthcare an...tial of strategic procurement, today announced tha...aceutical research and development,firm, has chose... and,enhance procurement functions for its operati...
... Peggy McKee (Recruiter and Owner of...t all. PHC Consulting is focused on top sales and ...ratory clinical and research, physician call point...2008 is a fantastic year for revenues and Peggy at... Celina, TX (PRWEB) June 24...
... Average Number of Days of Inpatient Therapy per P...sed by 10 Percent, According to New Dat...N, Penn., June 25 Arlington Medical Resources,(AM...the pharmaceutical and,diagnostic imaging industri... an antibiotic associated with a positive culture ...
Other Biology Technology:SciQuest Announces Newest Life Sciences Customer; BioMarin Pharmaceutical Drives Spending Effectiveness with Automated, Intuitive Procurement 2Website and Blog Increase Placement for Medical Sales Recruiter - Providing Sales Winners Calling on the Hospital, Lab and Physician Call Point 2Number of Patients Treated with an Antibiotic for MRSA Within U.S. Acute Care Hospitals Increased 8 Percent from 2006 to 2007 2
(Date:11/3/2009)... 4, 2009) For more than 25 years, all attempts at...gigas ) have been unsuccessfuluntil now. For the f...s to produce beaded (nucleated) and non-beaded cul...ped by scientists from Florida Atlantic University...ith less than two years of research and experiment...
(Date:11/3/2009)...ling of fruit and vegetables is a new, patented te...r beam is used to label, or "etch" information on ...ticker-type labels. The technology has been licens...nd is being used in New Zealand, Australia, and Pa...Asia, South Africa, Central and South America, Can...
(Date:11/3/2009)...ry Samueli School of Engineering and Applied Scien...ted in the laboratory the enzyme responsible for p... lovastatin. , The research, published Oct. 2... to the development of other compounds with simila...hesizing enzyme is one of the most interesting but...
Breaking Biology News(10 mins):Scientists are first to 'unlock' the mystery of creating cultured pearls from the queen conch 2Scientists are first to 'unlock' the mystery of creating cultured pearls from the queen conch 3Laser etching safe alternative for labeling grapefruit 2UCLA researchers reconstitute enzyme that synthesizes cholesterol drug lovastatin 2Patient perception is vital when reporting medical errors 55871 1Patient perception is vital when reporting medical errors 55871 2Why dont brain tumors respond to medication 3F 9755 1Why dont brain tumors respond to medication 3F 9755 2International event brings worlds top cancer doctors to Queens 9750 1International event brings worlds top cancer doctors to Queens 9750 2International event brings worlds top cancer doctors to Queens 9750 3
...broccoli!" Although parents may have good intentio...etables, this approach may backfire the very next ...sity. , "We found that the more controlling the p...ir plate, the more likely the kids, especially the...d cereal at daycare," says lead author Brian Wansi...
... is available in Spanish . , The Amazon is sur...esearch conducted throughout the world,s largest t... in Science , provides the first solid evidence t... forests, mainly through killing trees. , "For ...own climate change. But relying on this subsidy f...
...lobal warming, scientists are exploring ways to pu...away. Trees already do this naturally through phot...mapped large rock formations in the United States ...e artificially harnessed to do the task at a vastl... at Columbia University,s Earth Institute and the ...
Other Biology News:Amazon carbon sink threatened by drought 2Geologists map rocks to soak CO2 from air 2Geologists map rocks to soak CO2 from air 3Geologists map rocks to soak CO2 from air 4
...ides an extremely fast and efficient single step m...other systems that require tedious optimization or...vantage of the highly selective StrepTactin Superf...siological conditions with low background. With th...
Dr. P Set - Monkey (Cynomolgus) Normal Tissue: Small Intestine from BioChain
Supercoiled DNA Ladder from Invitrogen
Rabbit Anti-CREB-2 (H-290) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
Biology Products: